Pasithea Therapeutics KTTA Q1 2026 earnings
Reported May 15, 2026 · After market close
EPS-$0.12Beat by $0.33
Revenue estimate$100.0K
EPS estimate-$0.45
Next report
Date not yet announcedVersus estimates
Diluted EPS
Q1 2026-$0.12Beat by $0.33
Q4 2025-$0.89Miss by $0.71Q4 2026-$0.18In lineQ3 2025-$0.41Q2 2025-$0.66Q1 2025-$1.61Ask the moment Pasithea Therapeutics reports.
Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.
Connect your AI
Claude
Questions, answered.
- When did Pasithea Therapeutics report Q1 2026 earnings?
- Pasithea Therapeutics (KTTA) reported Q1 2026 earnings on May 15, 2026 after market close.
- What were Pasithea Therapeutics's Q1 2026 revenue and EPS?
- Pasithea Therapeutics reported eps of $-0.12 for Q1 2026.
- Did Pasithea Therapeutics beat estimates in Q1 2026?
- EPS beat the consensus estimate of $-0.45 by $0.33.
- How did Pasithea Therapeutics's Q1 2026 results compare year-over-year?
- Compared to the same quarter a year prior, eps grew 92.5% from $-1.61.
- Where can I find Pasithea Therapeutics's Q1 2026 SEC filings?
- You can read the 10-Q periodic report (0001213900-26-057837) directly on SEC EDGAR. The filing index links above go to sec.gov.